Product Description
Deferasirox is used to remove excess iron from the body in patients who have had too many blood transfusions and in patients with non-transfusion dependent thalassemia syndromes. Deferasirox is an iron chelator (binder). It combines with iron in the blood. The combination of iron and deferasirox is then removed from the body by the kidneys. If you have too much iron in the body, it can damage various organs and tissues. (Sourced from: https://www.mayoclinic.org/drugs-supplements/deferasirox-oral-route/side-effects/drg-20070776?p=1)
Mechanisms of Action: Iron Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Thalassemia | Iron Overload
Known Adverse Events: Abdominal Pain | Pain Unspecified | Transfusion Reaction | Iron Overload | Diarrhea
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: France
Active Clinical Trial Count: 8
Highest Development Phases
Phase 2: Anemia, Sickle Cell|Hemochromatosis|Iron Overload|Myelodysplastic Syndrome|Preleukemia|beta-Thalassemia
Phase 1: Healthy Volunteers|Ranula
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| LODEFI | P2 |
Completed |
Myelodysplastic Syndrome|Preleukemia |
2024-10-01 |
|
| 2016-002529-12 | P2 |
Active, not recruiting |
Hemochromatosis |
2020-11-16 |
|
| 2015-003532-12 | P2 |
Active, not recruiting |
beta-Thalassemia |
2020-03-27 |
|
| Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease | P2 |
Active, not recruiting |
Anemia, Sickle Cell|Iron Overload |
2020-03-05 |